Literature DB >> 30661412

The Use of Functional Near-Infrared Spectroscopy to Differentiate Alcohol-Related Neurodevelopmental Impairment.

Catherine E Barrett1, Julie A Kable1,2, Teresa E Madsen1, Chia-Chun Hsu1, Claire D Coles1,2.   

Abstract

Oxygenated (HBO) and deoxygenated hemoglobin (HBR) levels in the prefrontal cortex (PFC) were measured using functional near-infrared spectroscopy (fNIRS) to determine if PFC activity during a cognitive inhibition task distinguishes children with prenatal alcohol exposure (PAE, n = 26) from both typically developing controls (n = 19) and a contrast group of children with other neurobehavioral problems (n = 14). Despite showing evidence of increased PFC activity in the non-inhibitory condition relative to controls, children in the PAE group displayed reduced PFC HBO and increased HBR relative to both other groups in the inhibitory condition, suggesting reduced PFC activity but increased oxygen consumption without sufficient oxygen replacement.

Entities:  

Mesh:

Year:  2019        PMID: 30661412      PMCID: PMC6423538          DOI: 10.1080/87565641.2019.1567734

Source DB:  PubMed          Journal:  Dev Neuropsychol        ISSN: 1532-6942            Impact factor:   2.253


  3 in total

1.  Neurodevelopmental Outcomes Associated with Prefrontal Cortical Deoxygenation in Children with Fetal Alcohol Spectrum Disorders.

Authors:  Julie A Kable; Claire D Coles; Sarah N Mattson
Journal:  Dev Neuropsychol       Date:  2020-01-08       Impact factor: 2.253

2.  Characterizing Alcohol-Related Neurodevelopmental Disorder: Prenatal Alcohol Exposure and the Spectrum of Outcomes.

Authors:  Claire D Coles; Wendy Kalberg; Julie A Kable; Barbara Tabachnick; Philip A May; Christina D Chambers
Journal:  Alcohol Clin Exp Res       Date:  2020-05-20       Impact factor: 3.928

3.  Fifty Years of Research on Prenatal Substances: Lessons Learned for the Opioid Epidemic.

Authors:  Lynn T Singer; Christina Chambers; Claire Coles; Julie Kable
Journal:  Advers Resil Sci       Date:  2020-10-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.